AstraZeneca/Merck Reinforce Lynparza’s Prostate Cancer Position With First-Line Data

The companies published data showing the drug was effective in patients with both homologous recombinant repair mutated and non-mutated disease.

AstraZeneca and Merck are closer to snagging a first-line prostate cancer label for Lynparza • Source: Shutterstock

AstraZeneca plc and Merck & Co., Inc.’s Lynparza (olaparib) has reinforced is lead among PARP inhibitors for prostate cancer with the publication of data from the Phase III PROpel trial showing the drug, combined with Johnson & Johnson’s Zytiga (abiraterone) and prednisone, resulted in lower risk of disease progression or death in first-line patients, irrespective of homologous recombination repair (HRR) mutation status.

Consequently, Lynparza stands to potentially gain access to a significantly larger share of the prostate cancer market, given both the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category